BEIJING, CHINA, Feb. 25 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) - Further to the previously announced cosmetics merger (press release Feb 5, 2010) negotiations with the cosmetic company Melem Secrets, and other business matters the company is pleased to report that it has completed a cosmetic micro-conglomerate merger.
Collagenna Skin Care Products Inc (Collagenna) is a thriving micro cosmetics company. Collagenna briefly ventured into the public markets in 2009 and subsequently rescinded that merger upon learning that the parent company at that time had certain undisclosed legal issues. Collagenna will manage Melem Secrets and use Melem as a direct marketing company for all Collagenna product lines.
A source close to HTDS' said, "We see new and innovative products of Collagenna's as a great asset for our long anticipated expansion into cosmetic field. These companies may not show a stunning market value at the present, however revenues in the $500,000 range and projected to reach 3 million in the next 8 to 10 quarters is considered quite aggressive in any economy. Collagenna did pull its own weight and did quite good as a public company in 2009 HTDS management believes that they have great prospects for the future."
Collagenna was acquired on all cash basis therefore the existing share structure of HTDS will remain undisturbed and unchanged.
In other company news the company is continuing its research and assessment of the regenerative medicine and the stem cell bank projects. Additional information will be released as it becomes available. The company has been made aware of certain rumors circulating in the investment community that its insiders are selling their position or will sell their position in March 2010. This is untrue. All insider sales are strictly governed by SEC Rule 144 and to date no such act has taken place nor are there any plans for this in March of 2010 or in the foreseeable future.
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
Advertisement
Collagenna Skin Care Products Inc (Collagenna) is a thriving micro cosmetics company. Collagenna briefly ventured into the public markets in 2009 and subsequently rescinded that merger upon learning that the parent company at that time had certain undisclosed legal issues. Collagenna will manage Melem Secrets and use Melem as a direct marketing company for all Collagenna product lines.
Advertisement
A source close to HTDS' said, "We see new and innovative products of Collagenna's as a great asset for our long anticipated expansion into cosmetic field. These companies may not show a stunning market value at the present, however revenues in the $500,000 range and projected to reach 3 million in the next 8 to 10 quarters is considered quite aggressive in any economy. Collagenna did pull its own weight and did quite good as a public company in 2009 HTDS management believes that they have great prospects for the future."
Collagenna was acquired on all cash basis therefore the existing share structure of HTDS will remain undisturbed and unchanged.
In other company news the company is continuing its research and assessment of the regenerative medicine and the stem cell bank projects. Additional information will be released as it becomes available. The company has been made aware of certain rumors circulating in the investment community that its insiders are selling their position or will sell their position in March 2010. This is untrue. All insider sales are strictly governed by SEC Rule 144 and to date no such act has taken place nor are there any plans for this in March of 2010 or in the foreseeable future.
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
